Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro

Cancer Letters

Volumn 198, Issue 1, 2003, Pages 21-27

  Sadanand, V ^a   Kankesan, J ^b   Yusuf, A ^b   Stewart, C ^b   Rutka, J T ^b,c   Thiessen, J J ^d   Ling, V ^e   Rao, P M ^b   Rajalakshmi, S ^b   Sarma, D S R ^b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; Astrocytoma; P glycoprotein; PSC 833

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; GLYCOPROTEIN P; VALSPODAR; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CYCLOSPORIN DERIVATIVE; CYSTEINE PROTEINASE INHIBITOR; PEPTIDE CHLOROMETHYL KETONE;

APOPTOSIS; ARTICLE; ASTROCYTOMA CELL; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ASTROCYTOMA; BRAIN TUMOR; CELL CULTURE; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CASPASES; CYCLOSPORINS; CYSTEINE PROTEINASE INHIBITORS; HUMANS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0142058819     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00270-2     Document Type: Article

References (42)

1. Cohen A.R., Wisoff J.H., Allen J.C., Epstein F. Malignant astrocytomas of the spinal cord. J. Neurosurg. 70:1989;50-54.
2. Nieder C., Nestle U. A review of current and future treatment strategies for malignant astrocytomas in adults. Strahlenther. Onkol. 176:2000;251-258.
3. Dietzmann K., Bossanyi P.V., Franke D.S. Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma. Zentralbl. Pathol. 140:1994;149-153.
4. Ashmore S.M., Thomas D.G., Darling J.L. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Anticancer Drugs. 10:1999;861-872.
5. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:1976;152-162.
6. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
7. Pardridge W.M., Golden P.L., Kang Y.S., Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 68:1997;1278-1285.
8. Gaillard P.J., van der Sandt I.C., Voorwinden L.H., Vu D., Nielsen J.L., de Boer A.G., et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17:2000;1198-1205.
9. Bradley G., Sharma R., Rajalakshmi S., Ling V. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res. 52:1992;5154-5161.
10. Lee C.H., Bradley G., Ling V. Expression of P-glycoprotein in normal and malignant rat liver cells. Cold Spring Harb. Symp. Quant. Biol. 59:1994;607-615.
11. Goldstein L.J. MDR1 gene expression in solid tumours. Eur. J. Cancer. 32A:1996;1039-1050.
12. Atadja P., Watanabe T., Xu H., Cohen D. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev. 17:1998;163-168.
13. Costanzi-Strauss E., Strauss B.E., Naviaux R.K., Haas M. Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp. Cell Res. 238:1998;51-62.
14. Candell J., Valle V., Soler M., Rius J. Acute intoxication with verapamil. Chest. 75:1979;200-201.
15. Wang Q., Yang H., Miller D.W., Elmquist W.F. Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem. Biophys. Res. Commun. 211:1995;719-726.
16. Twentyman P.R., Bleehen N.M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur. J. Cancer. 27:1991;1639-1642.
17. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51:1991;4226-4233.
18. Newman M.J., Dixon R., Toyonaga B. OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy. Novartis Found. Symp. 243:2002;213-226. (discussion pp. 226-230, 231-235).
19. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61:2001;749-758.
20. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:1993;4595-4602.
21. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:1996;4171-4179.
22. Oza A.M. Clinical development of P glycoprotein modulators in oncology. Novartis Found. Symp. 243:2002;103-115. (discussion pp. 115-118, 180-185).
23. Tai H.L. Technology evaluation: Valspodar, Novartis AG. Curr. Opin. Mol. Ther. 2:2000;459-467.
24. Fracasso P.M., Brady M.F., Moore D.H., Walker J.L., Rose P.G., Letvak L., et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 19:2001;2975-2982.
25. Fracasso P.M., Westervelt P., Fears C.L., Rosen D.M., Zuhowski E.G., Cazenave L.A., et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J. Clin. Oncol. 18:2000;1124-1134.
26. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 100:2002;1224-1232.
27. Dorr R., Karanes C., Spier C., Grogan T., Greer J., Moore J., et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol. 19:2001;1589-1599.
28. Lehne G., Rugstad H.E. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein. Br. J. Cancer. 78:1998;593-600.
29. Cabot M.C., Giuliano A.E., Han T.Y., Liu Y.Y. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 59:1999;880-885.
30. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., Cabot M.C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer. 86:1999;300-311.
31. Bezombes C., Maestre N., Laurent G., Levade T., Bettaieb A., Jaffrezou J.P. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J. 12:1998;101-109.
32. Robinson L.J., Roberts W.K., Ling T.T., Lamming D., Sternberg S.S., Roepe P.D. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry. 36:1997;11169-11178.
33. Johnstone R.W., Cretney E., Smyth M.J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 93:1999;1075-1085.
34. Webber M.M., Bello-DeOcampo D., Quader S., Deocampo N.D., Metcalfe W.S., Sharp R.M. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin. Exp. Metastasis. 17:1999;255-263.
35. Smyth M.J., Krasovskis E., Sutton V.R., Johnstone R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl Acad. Sci. USA. 95:1998;7024-7029.
36. Ruefli A.A., Tainton K.M., Darcy P.K., Smyth M.J., Johnstone R.W. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 9:2002;1266-1272.
37. Pallis M., Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 95:2000;2897-2904.
38. Ruvolo P.P. Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia. 15:2001;1153-1160.
39. Haimovitz-Friedman A., Kolesnick R.N., Fuks Z. Ceramide signaling in apoptosis. Br. Med. Bull. 53:1997;539-553.
40. Perry D.K., Hannun Y.A. The role of ceramide in cell signaling. Biochim. Biophys. Acta. 1436:1998;233-243.
41. van Helvoort A., Giudici M.L., Thielemans M., van Meer G. Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J. Cell Sci. 110:(Pt 1):1997;75-83.
42. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15:2001;719-730.